TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Visual acuity impairment caused by macular edema in at least one eye~* Type 1 or type 2 diabetes mellitus~* Stable medication of diabetes in past 3 month~Exclusion Criteria:~* Patients with uncontrolled systemic or ocular diseases~* Laser photocoagulation in the study eye for the last 3 months~* Any history of any intraocular surgery in the study eye within the past 3 months~* Blood pressure \> 160/100 mmHg~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active laser photocoagulation and ranibizumab (Type: EXPERIMENTAL): Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
- Active laser photocoagulation and sham injection (Type: ACTIVE_COMPARATOR): Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Inhibitors of the Way JAK-STAT on Regulatory B Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* General criteria~* Patient, of 18 and more years old~* Subject affiliated to a social security system~* Subject not being in period of exclusion with regard to another protocol~* Absence of pregnancy in the inclusion (date of the last period, use of a contraceptive method, ß -HCG impulsive person in case of doubt)~* Informed consent~* Criteria of inclusion of the group rheumatoid arthritis (in vitro studies):~* Rheumatoid arthritis, corresponding to the the classification ACR / EULAR 2010 criteria~* Criteria of inclusion of the group arthritis (in vitro studies):~* Spinal degenerative osteoarthritis or degenerative osteoarthritis of the members, according to the clinical and radiological elements.~* Criteria of inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors :~* Rheumatoid Polyarthritis, corresponding to the classification ACR / EULAR 2010 criteria~* Patient to whom a treatment by inhibitor of the way JAK / STAT was proposed in current care of rheumatoid arthritis.~Exclusion criteria:~* General criteria~* Corticosteroid therapy superior to 10 mg / j~* Drip of corticoids in the previous month~* Pregnant or breast-feeding Patients~* Patient under protection(saving) of justice~* Under guardianship Patient or guardianship~* Current Infection~* Criteria of non-inclusion of the group rheumatoid polyarthritis ( in vitro studies):~* Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab) in the previous year~* Criteria of non-inclusion of the group arthritis ( in vitro studies):~* History of autoimmune disease or néoplasie~* Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab)~* Criteria of non-inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors :~Treatment by rituximab in the previous year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Rheumatoid arthritis (Type: OTHER): Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
- Osteoarthritis (Type: OTHER): Control patients and Blood sample analysis of patients treated as standard care
- Rheumatoid arthritis with JAK/STAT inhibitors (Type: OTHER): Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Inclusion Criteria:~  * Information concerning the study set-up, objectives, constraints and the patient's rights is transmitted~ * The patient and/or their legal guardian must have given their free and informed consent. If the patient is over 18, it is the patient who signs the consent form~ * The patient must be a member or beneficiary of a health insurance plan~* Exclusion Criteria:~  * The patient is under state guardianship or safeguard of justice~ * Refusal to sign the consent~ * It is impossible to give the subject informed information~ * Pregnant, parturient or breast feeding patient

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a diagnosis of clinically definite MS with a relapsing disease course as determined by the Poser criteria~2. Patients must be on high dose interferon therapy (Betaseron® 250 µg or Rebif® 44 µg) for at least 1 year prior to study entry~3. Patients must have experienced at least one documented relapse during the past year prior to screening. Pseudo-relapses must be ruled out. A gadolinium enhancing lesion is not required.~4. Patients must be ambulatory, with a Kurtzke EDSS score between 0-5 inclusive~5. Patients must be between the ages of 18 and 50 years inclusive~6. Women of childbearing potential must practice an acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, double-barrier method (condom or IUD with spermicide), or partner's vasectomy~7. Patients must be relapse-free and off corticosteroids (IV or oral) for at least 30 days prior to the screening visit~8. Patients must be relapse-free and off corticosteroids between the screening and baseline visits~9. Patients must be willing and able to give written informed consent~Exclusion Criteria:~1. Use of experimental or investigational drugs, and/or participation in an investigational drug study within 6 months prior to study entry~2. Previous treatment with glatiramer acetate (injectable)~3. Previous treatment with immunomodulators (except IFNβ), immunosuppressive agents, IVIG, or plasma exchange in the 6 months prior to screening; previous treatment with cladribine in the past 2 years~4. Previous total body irradiation or total lymphoid irradiation~5. Chronic corticosteroid (IV, IM, and/or PO) treatment (more than 30 consecutive days) in the 6 months prior to study entry~6. Pregnancy or breastfeeding~7. Life-threatening or other clinically significant disease~8. Any condition which the investigator feels may interfere with participation in the study, including alcohol and/or drug abuse~9. A known sensitivity to gadolinium (gadolinium acid)~10. A known history of sensitivity to mannitol~11. Inability to successfully undergo MRI scanning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Glatiramer Acetate 20 mg s.c. daily
- 2 (Type: ACTIVE_COMPARATOR): Betaseron 250 ug every other day or Rebif 44 ug 3 times a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Muscle Weakness in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute respiratory failure requiring mechanical ventilation~Exclusion Criteria:~* Attending physician on service determines that patient too unstable to tolerate measurements~* Patient requires \> 15mcg/min norepinephrine or \> 15mg/kg/min of dopamine.~* Fraction of inspired oxygen \> 80% or positive end expiratory pressure \> 15 cm H20 requirements.~* Cardiac pacemaker or implanted defibrillator.~* Neuromuscular blocking agents delivered within 48 hours of preceding testing.~* Existing neuromuscular disease.~* Profound uncorrectable hypokalemia (\< 2.5) OR hypophosphatemia (\< 1.0)~* Acute lower extremity deep vein thrombosis~* Pregnancy~* Prisoner~* Institutionalized patient~* If primary attending determines that patient is terminal and will likely have care withdrawn within 7 days~* Do not resuscitate order~* Body mass index \> 40~* Patients requiring mechanical ventilation more than 4 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham Treatment (Type: SHAM_COMPARATOR): Sham stimulation twice daily
- Active Treatment (Type: ACTIVE_COMPARATOR): The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 50-85 years-old~* self-reported OAB symptoms for ≥3 months~* a mean of ≥8 micturitions/ 24 hr~* ≥3 urgency episodes/24 hr on a 3-day bladder diary~* at least some moderate problems on the Patient Perception of Bladder Condition (PPBC)~* Montreal cognitive assessment (MOCA) score ≥24~* Stable dose of dopaminergic medications and levodopa (between 300 and 1200 mg daily)~Exclusion Criteria:~* Urinary retention: PVR \>150 ml (as assessed by bladder scan)~* Contra-indications to fesoterodine~* Unwilling to stop current antimuscarinics~* Patients on anticholinergics for motor disturbances~* Dementia based on clinical evaluation~* Atypical Parkinsonian syndrome~* Deep brain stimulation~* Presence of hallucination

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
- Fesoterodine (Type: EXPERIMENTAL): Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Epilepsia partialis continua or refractory status epilepticus~* Prior investigations (EEG, MRI...) show a well-defined neocortical epileptogenic focus~* Informed consent signed by the patient or his/her legal representative~Exclusion Criteria:~* Pregnancy, short-term birth wish or childbearing age without adequate birth control~* Intracranial metal hardware (excluding dental filling): surgical clips, shrapnell, electrodes under the stimulation area~* Presence of pacemaker, implantable cardioverter-defibrillator (ICD), permanent medication pumps, cochlear implants or deep brain stimulation (DBS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- repetitive transcranial magnetic stimulation (Type: EXPERIMENTAL): rTMS delivered over the epileptogenic focus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* early stage breast cancer between 2006-2009~* preoperative MRI~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants on hemodialysis between the ages of 18 and 70 years, with serum potassium levels of at least 5.5 mmol/L~* Adequately dialyzed (Kt/V ≥ 1.2)~Exclusion Criteria:~* History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery.~* Severe constipation or irregular bowel habits.~* Unable to consume or tolerate the study-specific diet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- patiromer (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to comply with the study protocol, in the investigator's judgment~* Completion of the treatment period as specified in the parent study~* Acceptable demonstration of tolerance to study drug during the parent study as determined by the investigator or Medical Monitor~* For participants receiving treatment with proton-pump inhibitors (PPIs) or H2-receptor antagonists (H2RAs), agreement to maintain treatment at a stable dose for the first 12 weeks of the study~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs~* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm~Exclusion Criteria~* Pregnant or breastfeeding, or intending to become pregnant during the study or within 4 weeks after the final dose of fenebrutinib~* Treatment with any investigational agent or live/attenuated vaccine in the preceding 6 weeks~* Any signs or symptoms of infection judged by the investigator to be clinically significant since completing the treatment period of the parent study~* Any significant changes (e.g., events, changes in medication) occurring after completion of participation in the parent study that, in the investigator's judgment, would increase the risk of adverse events in this OLE study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Parent Study: GDC-0853 (Type: EXPERIMENTAL): Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
- Parent Study: Placebo (Type: PLACEBO_COMPARATOR): Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PreColo Practice Variation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 75 years and above~* Scheduled for colon cancer surgery~Exclusion Criteria:~* Not receiving surgery~* Hematogenous metastasis~* Pretreatment; chemotherapy or radiotherapy~* Rectal cancer

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prehabilitation (Type: None): The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
- Usual care (Type: None): Guideline based colon cancer surgery, without prehabilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-existing diagnosis of asthma~* Persistent, moderate or severe asthma as classified by NAEPP~* Sub-optimally controlled asthma~* Initiated ICS therapy for at least the past 30 days and a history of improvement of asthma control on steroids~Exclusion Criteria:~* Active cigarette smoking or ≥ 10 pack-years smoking history~* Xolair taken in the past 6 months prior to enrollment~* Oral prednisone taken in the last 4 weeks prior to enrollment~* Cystic Fibrosis, COPD, ciliary dyskinesia, chest wall deformities or scoliosis~* Subject is currently enrolled in another investigational drug study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eNO group (Type: ACTIVE_COMPARATOR): eNO measurement is used to inform asthma management decisions
- control group (Type: NO_INTERVENTION): Asthma is managed according to existing standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improved Fertility After Exercise in Overweight/Obese Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* body mass index (weight in kg/height in cm squared) \>25~* accepted for assisted fertilization treatment at St.Olav's hospital~Exclusion Criteria:~* low responders, defined as AMH \<2 pmol/L or \< 5 oocytes in prior in vitro fertilisation (IVF)/Intracytoplasmic sperm injection (ICSI) cycles or antral follicle count (AFC) \< 5~* current or previous Metformin use (a wash-out period of \> four weeks)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Exercise (Type: EXPERIMENTAL): Regular exercise training for 10 weeks prior to assisted fertilisation
- Control (Type: NO_INTERVENTION): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sulfasalazine in Treating Painful Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Painful neuropathy~* Michigan Neuropathy Screening Instrument score of 3 or greater~* no obvious alternative explanation for neuropathy~* average baseline pain \> 4/10~Exclusion Criteria:~* other severe pain~* anticipated difficulty weaning off medications~* past or current psychiatric disorder as determined by Mini International Neuropsychiatric Interview~* medical contraindication to sulfasalazine~* not proficient in English (due to heavy use of questionaires)~* pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sulfasalazine (Type: EXPERIMENTAL): 1 g oral twice daily for 2 weeks
- placebo (Type: PLACEBO_COMPARATOR): oral placebo pill twice daily for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues